GlassScriptPhysician profile
Leah Monteilh
NPI 1184318503
$3,904.06
in general payments reported to CMS, 2019-2025
22 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $629 · 2024: $2,038 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,793 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,792.57 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.98 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $620.62 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $547.93 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $528.16 | 2024-2025 | Auvelity |
| Lundbeck LLC | $237.78 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $225.13 | 2023-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $143.23 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| Sage Therapeutics, LLC | $118.36 | 2023 | |
| Itamar Medical INC | $98.22 | 2023 | Watchpatone |
| Tris Pharma INC | $90.12 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Genzyme Corporation | $89.94 | 2024 | |
| Janssen Pharmaceuticals, INC | $88.71 | 2024-2025 | Spravato |
| Alkermes, INC. | $84.74 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $81.24 | 2023-2024 | Rexulti, Abilify Asimtufii |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.62 | 2025 | Cobenfy |
| Indivior INC. | $33.59 | 2024 | Sublocade |
| Exact Sciences Corporation | $17.88 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $17.06 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $16.65 | 2024 | Pifeltro, Delstrigo |
| Braeburn INC. | $15.87 | 2024 | Brixadi |
| Dexcom, INC. | $14.23 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Monteilh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.